Kehinde Adekola is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 73 publications with 2,330 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
675 N Saint Clair St
Galter 21-100
Chicago, IL 606115975
Telephone
312-695-0990Registry record last updated 19 Sept 2014.
Clinical trials
- Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20259 payments
- National Marrow Donor ProgramProgram year20255 payments
- National Marrow Donor ProgramProgram year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
69.6%Human Immunoglobulin G51.3%Immune globulin100%Part B, office-administered≥12 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.5%Valacyclovir100%Part D≥28 patients+ 2 more classes in this area
Metabolism & gastrointestinal
12%Bile Acid7.4%Ursodiol100%Part D≥24 patientsProton pump inhibitor2.3%Pantoprazole Sodium67%Omeprazole33%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
6.6%Kinase inhibitor3.7%Jakafi100%Part D≥13 patientsOther protein kinase inhibitors1.2%Xospata100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”